-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AI pharmacy is different from traditional pharmacy.
It has the advantages of shortening the new drug research and development cycle, improving the success rate of new drug research and development, and reducing the cost in the pharmaceutical process, which can bring rich returns to enterprises
.
Therefore, in recent years, with the rapid development of new-generation information technologies such as 5G, cloud computing, and big data, AI has begun to play an increasingly important role in the field of drug research and development
.
At the same time, the cooperation between pharmaceutical companies and AI companies has become more and more
.
Recently, Hengrui Medicine signed a strategic cooperation agreement with Iktos of France on the AI new drug research and development platform
.
According to data, Iktos is a company headquartered in Paris, France, specializing in the development of artificial intelligence new drug design platforms
.
According to the agreement, Hengrui will use Iktos' AI-based de novo drug design software Makya™ to accelerate the discovery of small molecule drugs and the optimization of lead compounds
.
In addition to Hengrui Medicine, in September this year, Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology also reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs
.
It is reported that in this cooperation, the two parties will focus on the research and development of innovative small-molecule antidepressant drugs with independent intellectual property rights, and apply AI technology to the design, optimization and verification of preclinical drug candidates for this project, and accelerate the development of drugs that are urgently needed by patients with depression
.
In addition, earlier, Simcere Pharmaceuticals and Almai Biotechnology have also jointly announced that the two parties have signed an exclusive license agreement for the new anti-tumor drug ALM005
.
According to the data, Almai Bio is a technology-based company that uses artificial intelligence drug screening and optimization technology to accelerate the development of new drugs, focusing on data-driven, using machine learning models to carry out lead compound design and discovery, drug multi-target selectivity, and optimized drug properties.
.
The ALM005 of this cooperation is based on Al Vein's AI technology and discovered very valuable compound molecules
.
From the above and the overall view of the pharmaceutical industry, it is very common for pharmaceutical companies to use AI to accelerate innovation in the industry
.
It is worth mentioning that in addition to pharmaceutical companies, Bytedance, Tencent, Baidu and other companies have actually already set foot in the AI pharmaceutical field.
.
For example, Tencent launched the AI drug discovery platform "Yunshen Pharmaceutical" in July 2020, and Baidu established the life science platform "Baitu Shengke" in September 2020.
.
.
In the context of giants getting together to lay out the AI pharmacy track, The industry believes that this means that the domestic AI new drug research and development industry has ushered in an active period and will have more and more room for development in the future
.
In this context, capital is expected to continue to increase its weight in the AI field
.
It is understood that data shows that in 2021, the entire AI pharmaceutical track will usher in the continued attention of more and more investors, and the amount of financing in the first half of the year has exceeded 1 billion yuan
.
Recently, there have been many financing news in the AI pharmaceutical field
.
For example, on October 15, Xunbaihui, which focuses on the research and development of innovative tumor immune AI drugs, announced that it has completed a tens of millions of dollars in Series B financing led by IDG Capital.
The funds raised will be used to promote the clinical development of new target antibody and new drug projects, and The research and development of multiple drug pipelines related to tumor immune targets; On October 13th, Jingwei Venture Capital and Wuyuan Capital jointly led the Pre-A round of Woshi Technology, with a transaction amount of nearly 10 million U.
S.
dollars.
.
.
The industry believes that at present It can be seen that the development of domestic AI pharmaceuticals is in full swing.
In the future, affected by this, drug R&D and innovation will continue to accelerate, and as innovations continue to emerge, more and more patients will also be benefited
.
It has the advantages of shortening the new drug research and development cycle, improving the success rate of new drug research and development, and reducing the cost in the pharmaceutical process, which can bring rich returns to enterprises
.
Therefore, in recent years, with the rapid development of new-generation information technologies such as 5G, cloud computing, and big data, AI has begun to play an increasingly important role in the field of drug research and development
.
At the same time, the cooperation between pharmaceutical companies and AI companies has become more and more
.
Recently, Hengrui Medicine signed a strategic cooperation agreement with Iktos of France on the AI new drug research and development platform
.
According to data, Iktos is a company headquartered in Paris, France, specializing in the development of artificial intelligence new drug design platforms
.
According to the agreement, Hengrui will use Iktos' AI-based de novo drug design software Makya™ to accelerate the discovery of small molecule drugs and the optimization of lead compounds
.
In addition to Hengrui Medicine, in September this year, Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology also reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs
.
It is reported that in this cooperation, the two parties will focus on the research and development of innovative small-molecule antidepressant drugs with independent intellectual property rights, and apply AI technology to the design, optimization and verification of preclinical drug candidates for this project, and accelerate the development of drugs that are urgently needed by patients with depression
.
In addition, earlier, Simcere Pharmaceuticals and Almai Biotechnology have also jointly announced that the two parties have signed an exclusive license agreement for the new anti-tumor drug ALM005
.
According to the data, Almai Bio is a technology-based company that uses artificial intelligence drug screening and optimization technology to accelerate the development of new drugs, focusing on data-driven, using machine learning models to carry out lead compound design and discovery, drug multi-target selectivity, and optimized drug properties.
.
The ALM005 of this cooperation is based on Al Vein's AI technology and discovered very valuable compound molecules
.
From the above and the overall view of the pharmaceutical industry, it is very common for pharmaceutical companies to use AI to accelerate innovation in the industry
.
It is worth mentioning that in addition to pharmaceutical companies, Bytedance, Tencent, Baidu and other companies have actually already set foot in the AI pharmaceutical field.
.
For example, Tencent launched the AI drug discovery platform "Yunshen Pharmaceutical" in July 2020, and Baidu established the life science platform "Baitu Shengke" in September 2020.
.
.
In the context of giants getting together to lay out the AI pharmacy track, The industry believes that this means that the domestic AI new drug research and development industry has ushered in an active period and will have more and more room for development in the future
.
In this context, capital is expected to continue to increase its weight in the AI field
.
It is understood that data shows that in 2021, the entire AI pharmaceutical track will usher in the continued attention of more and more investors, and the amount of financing in the first half of the year has exceeded 1 billion yuan
.
Recently, there have been many financing news in the AI pharmaceutical field
.
For example, on October 15, Xunbaihui, which focuses on the research and development of innovative tumor immune AI drugs, announced that it has completed a tens of millions of dollars in Series B financing led by IDG Capital.
The funds raised will be used to promote the clinical development of new target antibody and new drug projects, and The research and development of multiple drug pipelines related to tumor immune targets; On October 13th, Jingwei Venture Capital and Wuyuan Capital jointly led the Pre-A round of Woshi Technology, with a transaction amount of nearly 10 million U.
S.
dollars.
.
.
The industry believes that at present It can be seen that the development of domestic AI pharmaceuticals is in full swing.
In the future, affected by this, drug R&D and innovation will continue to accelerate, and as innovations continue to emerge, more and more patients will also be benefited
.
